<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990821</url>
  </required_header>
  <id_info>
    <org_study_id>0517-012</org_study_id>
    <secondary_id>MK-0517-012</secondary_id>
    <nct_id>NCT00990821</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)</brief_title>
  <official_title>A Randomized, 5-Part, Intravenous Study of the Safety, Tolerability, Bioequivalence, and Drug Interaction Potential of Final Market Image Formulation of MK0517 in Young Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This 5-part study will evaluate the safety, tolerability, and pharmacokinetics of two
      formulations of MK-0517 (with and without polysorbate 80) and aprepitant in healthy adults.
      Parts I to IV of this study will examine different doses of MK-0517 as well as two different
      formulations of MK-0517 (with and without polysorbate 80). Part V of the study will compare
      single doses of intravenous non-PS80 MK-0517 to oral 125-mg capsule of aprepitant. The
      primary hypothesis for Part V of the study is that a single intravenous dose of 100-mg or
      115-mg MK-0517 is area under the plasma-time curve (AUC) equivalent to that of the 125-mg
      oral aprepitant capsule in young healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma-Time Curve (AUC[0 to Infinity]) for Aprepitant and MK-0517 for Study Part V</measure>
    <time_frame>Up to 72 Hours Post Dose</time_frame>
    <description>AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time. The AUC(0-inf) bioequivalence was evaluated for single doses of 100 and 115 mg MK-0517 PS80, IV and that of an oral 125-mg capsule of aprepitant. Period I to IV populations are not included in the outcome analysis because those were formulation and dose-finding/dose confirmation arms.</description>
  </primary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Chemotherapy-Induced Nausea and Vomiting</condition>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Part I, Panel A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg MK-0517 (nonpolysorbate 80 formulation [non-PS80]) or placebo → 150 mg MK-0517 (non- PS80) or placebo → 125 mg aprepitant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I, Panel B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg MK-0517 (PS80 formulation [PS80]) or placebo → 150 mg MK-0517 (PS80) or placebo → 125 mg aprepitant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I, Panel C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg MK-0517 (non-PS80) or placebo → 40 mg aprepitant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg midazolam → 100 mg MK-0517 (PS80) + 2 mg midazolam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part III, Panel 1, Treatment Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125 mg aprepitant → 90 mg MK-0517 (PS80)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part III, Panel 1, Treatment Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg MK-0517 (non-PS80) → 125 mg aprepitant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part III, Panel 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg MK-0517 (non-PS80)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg MK-0517 (non-PS80 formulation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part V, Treatment Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125 mg aprepitant → 100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80 formulation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part V, Treatment Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80) → 125 mg aprepitant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part V, Treatment Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>115 mg MK-0517 (PS80) → 125 mg aprepitant → 100 mg MK-0517 (PS80)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part V, Treatment Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125 mg aprepitant → 115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part V, Treatment Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg MK-0517 (PS80) → 125 mg aprepitant → 115 mg MK-0517 (PS80)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part V, Treatment Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80) → 125 mg aprepitant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90 mg MK-0517 (PS80)</intervention_name>
    <description>MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes</description>
    <arm_group_label>Part III, Panel 1, Treatment Sequence 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg MK-0517 (PS80)</intervention_name>
    <description>MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes</description>
    <arm_group_label>Part I, Panel B</arm_group_label>
    <arm_group_label>Part II</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 1</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 2</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 3</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 4</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 5</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 MK-0517 (PS80) + 2 mg midazolam</intervention_name>
    <description>MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral 2-mg dose of midazolam with MK-0517.</description>
    <arm_group_label>Part I, Panel A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>115 mg MK-0517 (PS80)</intervention_name>
    <description>MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes</description>
    <arm_group_label>Part V, Treatment Sequence 1</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 2</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 3</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 4</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 5</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150 mg MK-0517 (PS80)</intervention_name>
    <description>MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes</description>
    <arm_group_label>Part I, Panel B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40 mg MK-0517 (non-PS80)</intervention_name>
    <description>MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.</description>
    <arm_group_label>Part I, Panel C</arm_group_label>
    <arm_group_label>Part III, Panel 1, Treatment Sequence 1</arm_group_label>
    <arm_group_label>Part III, Panel 1, Treatment Sequence 2</arm_group_label>
    <arm_group_label>Part III, Panel 2</arm_group_label>
    <arm_group_label>Part IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg MK-0517 (non-PS80)</intervention_name>
    <description>MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.</description>
    <arm_group_label>Part I, Panel A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150 mg MK-0517 (Non-PS80)</intervention_name>
    <description>MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.</description>
    <arm_group_label>Part I, Panel A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching MK-0517</description>
    <arm_group_label>Part I, Panel A</arm_group_label>
    <arm_group_label>Part I, Panel B</arm_group_label>
    <arm_group_label>Part I, Panel C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40 mg Aprepitant</intervention_name>
    <description>Aprepitant, oral, tablet, single dose</description>
    <arm_group_label>Part I, Panel C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>125 mg Aprepitant</intervention_name>
    <description>Aprepitant oral tablet, single dose</description>
    <arm_group_label>Part I, Panel A</arm_group_label>
    <arm_group_label>Part I, Panel B</arm_group_label>
    <arm_group_label>Part III, Panel 1, Treatment Sequence 1</arm_group_label>
    <arm_group_label>Part III, Panel 1, Treatment Sequence 2</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 1</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 2</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 3</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 4</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 5</arm_group_label>
    <arm_group_label>Part V, Treatment Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 mg Midazolam</intervention_name>
    <description>Midazolam oral tablet, single dose</description>
    <arm_group_label>Part II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is neither grossly overweight nor underweight for his/her height and body
             build

          -  Subject is in good health -Subject is a nonsmoker

          -  Subject is willing to avoid excessive alcohol consumption for the duration of the
             study

          -  Subject is willing to avoid strenuous physical activity (i.e. unaccustomed weight
             lifting, running, bicycling) for the duration of the study

          -  Subject agrees to refrain from consumption of grapefruit (and grapefruit products)
             before and during the study

        Exclusion Criteria:

          -  Subject has a history of multiple and/or severe allergies to drugs or food

          -  Subject has donated blood or taken an investigational drug in another clinical trial
             within the last 4 weeks

          -  Subject has an infection, including Human immunodeficiency virus (HIV) infection

          -  Subject is a regular user of any illicit drug

          -  Subject consumes excessive amounts of alcohol

          -  Subject drinks excessive amounts of coffee, tea, cola or other caffeinated beverages

          -  Subject currently uses on a regular basis, any prescription or non prescription
             medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2009</study_first_submitted>
  <study_first_submitted_qc>October 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <results_first_submitted>April 9, 2010</results_first_submitted>
  <results_first_submitted_qc>October 21, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2013</results_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One Investigator in the United States. Primary therapy period: 31-Jan-2005 to 01-Dec-2005.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Part I, Panel A</title>
          <description>100 mg MK-0517 (non-polysorbate 80 formulation [non-PS80]) or placebo → 150 mg MK-0517 (non-PS80) or placebo → 125 mg aprepitant</description>
        </group>
        <group group_id="P2">
          <title>Part I, Panel B</title>
          <description>100 mg MK-0517 (PS80 formulation [PS80]) or placebo → 150 mg MK-0517 (PS80) or placebo → 125 mg aprepitant</description>
        </group>
        <group group_id="P3">
          <title>Part I, Panel C</title>
          <description>40 mg MK-0517 (non-PS80) or placebo → 40 mg aprepitant</description>
        </group>
        <group group_id="P4">
          <title>Part II</title>
          <description>2 mg midazolam → 100 mg MK-0517 (PS80) + 2 mg midazolam</description>
        </group>
        <group group_id="P5">
          <title>Part III, Panel 1, Treatment Sequence 1</title>
          <description>125 mg aprepitant → 90 mg MK-0517 (PS80)</description>
        </group>
        <group group_id="P6">
          <title>Part III, Panel 1, Treatment Sequence 2</title>
          <description>40 mg MK-0517 (non-PS80) → 125 mg aprepitant</description>
        </group>
        <group group_id="P7">
          <title>Part III, Panel 2</title>
          <description>40 mg MK-0517 (non-PS80)</description>
        </group>
        <group group_id="P8">
          <title>Part IV</title>
          <description>40 mg MK-0517 (non-PS80 formulation)</description>
        </group>
        <group group_id="P9">
          <title>Part V, Treatment Sequence 1</title>
          <description>125 mg aprepitant → 100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80 formulation)</description>
        </group>
        <group group_id="P10">
          <title>Part V, Treatment Sequence 2</title>
          <description>100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80) → 125 mg aprepitant</description>
        </group>
        <group group_id="P11">
          <title>Part V, Treatment Sequence 3</title>
          <description>115 mg MK-0517 (PS80) → 125 mg aprepitant → 100 mg MK-0517 (PS80)</description>
        </group>
        <group group_id="P12">
          <title>Part V, Treatment Sequence 4</title>
          <description>125 mg aprepitant → 115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80)</description>
        </group>
        <group group_id="P13">
          <title>Part V, Treatment Sequence 5</title>
          <description>100 mg MK-0517 (PS80) → 125 mg aprepitant → 115 mg MK-0517 (PS80)</description>
        </group>
        <group group_id="P14">
          <title>Part V, Treatment Sequence 6</title>
          <description>115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80) → 125 mg aprepitant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="17"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="14"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="14"/>
                <participants group_id="P13" count="12"/>
                <participants group_id="P14" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="14"/>
                <participants group_id="P7" count="11"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="13"/>
                <participants group_id="P11" count="9"/>
                <participants group_id="P12" count="9"/>
                <participants group_id="P13" count="10"/>
                <participants group_id="P14" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part I, Panel A</title>
          <description>100 mg MK-0517 (non-polysorbate 80 formulation [non-PS80]) or placebo → 150 mg MK-0517 (non-PS80) or placebo → 125 mg aprepitant</description>
        </group>
        <group group_id="B2">
          <title>Part I, Panel B</title>
          <description>100 mg MK-0517 (PS80 formulation [PS80]) or placebo → 150 mg MK-0517 (PS80) or placebo → 125 mg aprepitant</description>
        </group>
        <group group_id="B3">
          <title>Part I, Panel C</title>
          <description>40 mg MK-0517 (non-PS80) or placebo → 40 mg aprepitant</description>
        </group>
        <group group_id="B4">
          <title>Part II</title>
          <description>2 mg midazolam → 100 mg MK-0517 (PS80) + 2 mg midazolam</description>
        </group>
        <group group_id="B5">
          <title>Part III, Panel 1, Treatment Sequence 1</title>
          <description>125 mg aprepitant → 90 mg MK-0517 (PS80)</description>
        </group>
        <group group_id="B6">
          <title>Part III, Panel 1, Treatment Sequence 2</title>
          <description>40 mg MK-0517 (non-PS80) → 125 mg aprepitant</description>
        </group>
        <group group_id="B7">
          <title>Part III, Panel 2</title>
          <description>40 mg MK-0517 (non-PS80)</description>
        </group>
        <group group_id="B8">
          <title>Part IV</title>
          <description>40 mg MK-0517 (non-PS80 formulation)</description>
        </group>
        <group group_id="B9">
          <title>Part V, Treatment Sequence 1</title>
          <description>125 mg aprepitant → 100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80 formulation)</description>
        </group>
        <group group_id="B10">
          <title>Part V, Treatment Sequence 2</title>
          <description>100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80) → 125 mg aprepitant</description>
        </group>
        <group group_id="B11">
          <title>Part V, Treatment Sequence 3</title>
          <description>115 mg MK-0517 (PS80) → 125 mg aprepitant → 100 mg MK-0517 (PS80)</description>
        </group>
        <group group_id="B12">
          <title>Part V, Treatment Sequence 4</title>
          <description>125 mg aprepitant → 115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80)</description>
        </group>
        <group group_id="B13">
          <title>Part V, Treatment Sequence 5</title>
          <description>100 mg MK-0517 (PS80) → 125 mg aprepitant → 115 mg MK-0517 (PS80)</description>
        </group>
        <group group_id="B14">
          <title>Part V, Treatment Sequence 6</title>
          <description>115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80) → 125 mg aprepitant</description>
        </group>
        <group group_id="B15">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="17"/>
            <count group_id="B6" value="17"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="14"/>
            <count group_id="B9" value="12"/>
            <count group_id="B10" value="14"/>
            <count group_id="B11" value="12"/>
            <count group_id="B12" value="14"/>
            <count group_id="B13" value="12"/>
            <count group_id="B14" value="12"/>
            <count group_id="B15" value="188"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.2" lower_limit="21" upper_limit="45"/>
                    <measurement group_id="B2" value="35.2" lower_limit="23" upper_limit="44"/>
                    <measurement group_id="B3" value="33.1" lower_limit="22" upper_limit="45"/>
                    <measurement group_id="B4" value="36.9" lower_limit="25" upper_limit="45"/>
                    <measurement group_id="B5" value="33.2" lower_limit="19" upper_limit="43"/>
                    <measurement group_id="B6" value="33.2" lower_limit="19" upper_limit="43"/>
                    <measurement group_id="B7" value="32.4" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B8" value="29.4" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B9" value="31.9" lower_limit="19" upper_limit="44"/>
                    <measurement group_id="B10" value="33.5" lower_limit="22" upper_limit="44"/>
                    <measurement group_id="B11" value="31.3" lower_limit="22" upper_limit="45"/>
                    <measurement group_id="B12" value="29.1" lower_limit="19" upper_limit="41"/>
                    <measurement group_id="B13" value="30.4" lower_limit="19" upper_limit="45"/>
                    <measurement group_id="B14" value="36.5" lower_limit="20" upper_limit="43"/>
                    <measurement group_id="B15" value="32.6" lower_limit="18" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="8"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma-Time Curve (AUC[0 to Infinity]) for Aprepitant and MK-0517 for Study Part V</title>
        <description>AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time. The AUC(0-inf) bioequivalence was evaluated for single doses of 100 and 115 mg MK-0517 PS80, IV and that of an oral 125-mg capsule of aprepitant. Period I to IV populations are not included in the outcome analysis because those were formulation and dose-finding/dose confirmation arms.</description>
        <time_frame>Up to 72 Hours Post Dose</time_frame>
        <population>All participants in Part V who had at least one period of AUC data were included in the evaluation of pharmacokinetics. Participants without sufficient concentration data for an AUC calculation included: 6 participants in the Aprepitant (125 mg) , 8 participants in the MK-0517 (100 mg) group, and 5 participants in the MK-0517 (115 mg) group.</population>
        <group_list>
          <group group_id="O1">
            <title>Aprepitant (125 mg)</title>
            <description>A single oral dose with an Aprepitant capsule</description>
          </group>
          <group group_id="O2">
            <title>MK-0517 (100 mg)</title>
            <description>100 mg of MK0517 (PS80 formulation) as an IV (intravenous) administered over 15 minutes</description>
          </group>
          <group group_id="O3">
            <title>MK-0517 (115 mg)</title>
            <description>115 mg of MK0517 (PS80 formulation) as an IV (intravenous) administered over 15 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma-Time Curve (AUC[0 to Infinity]) for Aprepitant and MK-0517 for Study Part V</title>
          <description>AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time. The AUC(0-inf) bioequivalence was evaluated for single doses of 100 and 115 mg MK-0517 PS80, IV and that of an oral 125-mg capsule of aprepitant. Period I to IV populations are not included in the outcome analysis because those were formulation and dose-finding/dose confirmation arms.</description>
          <population>All participants in Part V who had at least one period of AUC data were included in the evaluation of pharmacokinetics. Participants without sufficient concentration data for an AUC calculation included: 6 participants in the Aprepitant (125 mg) , 8 participants in the MK-0517 (100 mg) group, and 5 participants in the MK-0517 (115 mg) group.</population>
          <units>ng*hr/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29215" spread="15731"/>
                    <measurement group_id="O2" value="24961" spread="10477"/>
                    <measurement group_id="O3" value="31724" spread="14287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 30 days after the last dose of study drug</time_frame>
      <desc>All 188 study participants are included in the safety population: Adverse events are reported for the actual doses given in any part of the study. Individual participants may have received more than one drug or more than one dose of a drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>90 mg MK-0517 (PS80)</title>
          <description>MK-0517, PS80 formulation, administered with a single IV administration</description>
        </group>
        <group group_id="E2">
          <title>100 mg MK-0517 (PS80)</title>
          <description>MK-0517, PS80 formulation, administered with a single IV administration</description>
        </group>
        <group group_id="E3">
          <title>100 mg MK-0517 (PS80) + 2 mg Midazolam</title>
          <description>PS80 formulation, administered with a single IV administration and a single oral administration of midazolam</description>
        </group>
        <group group_id="E4">
          <title>115 mg MK-0517 (PS80)</title>
          <description>MK-0517, PS80 formulation, administered with a single IV administration</description>
        </group>
        <group group_id="E5">
          <title>150 mg MK-0517 (PS80)</title>
          <description>MK-0517, PS80 formulation, administered with a single IV administration</description>
        </group>
        <group group_id="E6">
          <title>40 mg MK-0517 (Non-PS80)</title>
          <description>MK-0517, non-PS80 formulation, administered with a single IV administration</description>
        </group>
        <group group_id="E7">
          <title>100 mg MK-0517 (Non-PS80)</title>
          <description>MK-0517, PS80 formulation, administered with a single IV administration</description>
        </group>
        <group group_id="E8">
          <title>150 mg MK-0517 (Non-PS80)</title>
          <description>MK-0517, PS80 formulation, administered with a single IV administration</description>
        </group>
        <group group_id="E9">
          <title>Placebo</title>
          <description>Placebo matching MK-0517 (PS80 or non-PS80)</description>
        </group>
        <group group_id="E10">
          <title>40 mg Aprepitant</title>
          <description>Aprepitant administered by a single oral capsule</description>
        </group>
        <group group_id="E11">
          <title>125 mg Aprepitant</title>
          <description>Aprepitant administered as a single oral capsule</description>
        </group>
        <group group_id="E12">
          <title>2 mg Midazolam</title>
          <description>Midazolam administered as a single oral solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Infusion Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular Pressure Test</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

